The Court of Justice of the EU has ruled that Italy’s decision to reimburse Roche’s Avastin (bevacizumab) for off-label use in wet age-related macular degeneration is not contrary to EU law.
The decision is yet another blow to Novartis AG, which together with Roche is involved in a long-running, and...








